News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Month Year

Month Year

Dec 10, 2018

Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
Dec 3, 2018

Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Nov 28, 2018

XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

- FLT3 mutation-positive AML is a life-threatening disease[1] with significant unmet medical needs -
Nov 20, 2018

Astellas Global Health Foundation Launches - Foundation to Support Improving Access to Health for Underserved Populations -
Nov 20, 2018

Astellas US LLC and the Academy of Oncology Nurse & Patient Navigators (AONN+) Announce Collaboration

Navigation Acuity Tool to be Developed by Astellas US LLC and AONN+
Nov 19, 2018

Astellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual Meeting

- Abstracts include updated results from Phase 1 study of gilteritinib in patients with newly diagnosed AML -
Nov 12, 2018

Astellas Appoints Eloiza Domingo-Snyder to Head of Diversity and Inclusion
- Photos 1
Oct 9, 2018

Astellas Details Progress and Commitment to Patients and the Community in the Company's Americas 2017 Corporate Social Responsibility Report Card
- Photos 1
Oct 4, 2018

Astellas Oncology Announces Grand Prize Winner of C3 Prize® at Union for International Cancer Control (UICC) World Cancer Congress

Three innovators working to change cancer care awarded a combined $100,000 in grants following live pitch to a panel of judges that included celebrity entrepreneur Bill Rancic
- Photos 1
Sep 25, 2018

Working Mother Magazine names Astellas among 100 best companies in the US across all industries

Astellas ranked in recognition of its commitment and support for working mothers
Sep 24, 2018

Astellas Farma Brasil named one of the best companies to work for in Brazil

Astellas recognized by Great Place to Work® Institute
Sep 24, 2018

Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs 14.7 months for men who received placebo plus ADT(1)
Sep 21, 2018

Astellas Oncology Announces C3 Prize® Celebrity Partnership and Category Winners

Bill and Giuliana Rancic to Lend Expertise, Passion and Personal Cancer Experience to Inspire Fellow Entrepreneurs
Sep 18, 2018

Astellas Promotes Geoff Towle to Vice President of Oncology Marketing at Astellas US
- Photos 1
Sep 14, 2018

Astellas Named a PM360 Trailblazer 2018 "Company of the Year"

--Additional marketing award received for Best Video/TV Campaign--
- Photos 1
Sep 13, 2018

More than 800 Astellas Employees Volunteer for 16 Community Organizations as Part of Ninth Annual Changing Tomorrow Day
- Photos 3
Sep 12, 2018

Astellas Announces Launch of "What's Next Sweepstakes" with Laila Ali

Winner Will Attend Live Taping of ABC's "Dancing with the Stars"
Aug 23, 2018

Astellas Appoints Shontelle Dodson to Senior Vice President Health Systems
- Photos 1
Aug 23, 2018

Astellas Promotes Rodrigo Fernandez to Vice President, Latin America
- Photos 1
Aug 22, 2018

Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer

Amendments accelerate anticipated primary completion dates for both ARCHES and EMBARK trials
Aug 16, 2018

Astellas Promotes David Abbott to National Vice President Key Account Management
- Photos 1
Aug 10, 2018

Astellas Announces Acquisition of Quethera

Acquisition furthers Astellas' commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma
Aug 3, 2018

Astellas Statement on U.S. Drug Pricing
Jul 23, 2018

Astellas Americas Announces Leadership Changes in Medical Affairs and Corporate Communications

Dr. Halit Bander named VP, Oncology, Medical Affairs; Moyra Knight named VP, Corporate Communications; Maribeth Landwehr named Executive Director, Corporate Communications
- Photos 3
Jul 13, 2018

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC
Jul 9, 2018

Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program

-Enrollment of EV-201 Pivotal Trial Cohort Designed to Support Potential Expedited Registration Pathway in the U.S. Completed-
Jun 19, 2018

Astellas Employees at National Sales Forum Support Five Anaheim-Area Non-Profits

Employees Also Raised More Than $55,000 at Third Annual "One Astellas Spirit Run" for Seven Charitable Organizations
- Video 1
- Photos 2
Jun 8, 2018

Astellas names Nahrin Marino to Vice President, Head of Ethics & Compliance Americas
- Photos 1
Jun 3, 2018

Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy

-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study-
May 31, 2018

Astellas Oncology C3 Prize® Returns for Third Year with Focus on Improving Cancer Care in Underserved Regions of the World

2018 Challenge Will Award a Total of $100,000 in New Grants to Help Reduce the Unequal Burden of Cancer
May 29, 2018

U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
May 16, 2018

Astellas Announces Abstracts Highlighting Growing Oncology Portfolio to be Presented at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 15, 2018

Astellas Appoints Bernhardt Zeiher, M.D., as New Chief Medical Officer

Joins Company's Executive Leadership Team
- Photos 1
May 7, 2018

FDA Approves Supplemental New Drug Application for Myrbetriq® (mirabegron) for Use in Combination with solifenacin succinate for the Treatment of Overactive Bladder Symptoms
May 2, 2018

Astellas Included in Forbes Best Midsize Employers List for Fourth Year
Apr 30, 2018

Astellas' Nahrin Marino named a 2018 Healthcare Businesswomen's Association Luminary
- Photos 1
Apr 26, 2018

Astellas Reports Financial Results for FY2017
Apr 23, 2018

Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia
Apr 18, 2018

Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company

Asset Transfer was Completed on April 12, 2018
- Photos 1
Apr 3, 2018

Astellas Named "Outstanding Employer" for Supporting Employees with Military Service
- Photos 1
Mar 28, 2018

Astellas Names Tatjana Dragovic, J.D. Head of Ethics & Compliance

Dragovic was previously Vice President, Ethics & Compliance Americas
- Photos 1
Mar 26, 2018

Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Mar 19, 2018

U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

sNDA Seeks to Expand the Indication of XTANDI to include Men with Non-metastatic CRPC
Mar 15, 2018

Astellas Names Percival Barretto-Ko President, Americas Operations

Barretto-Ko was previously Senior Vice President, International Operations
- Photos 1
Mar 13, 2018

Astellas Announces Key Leadership Changes in Legal, Human Resources
- Photos 1
Feb 13, 2018

Astellas Acquires Universal Cells, Inc.

Acquisition enables Astellas to fully utilize proprietary technology to produce pluripotent stem cells that have the potential to lower immunological rejection in numerous therapeutic areas
Feb 5, 2018

Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer
Jan 31, 2018

Astellas Reports Financial Results for the First Nine Months of FY2017
Jan 29, 2018

Astellas to Present New Oncology Data at the 2018 ASCO Genitourinary Cancers (GU) Symposium

- A total of 10 abstracts and one trial in progress (TIP) across various cancers to be presented during oral and poster sessions -
- Photos 1
Jan 23, 2018

Astellas Completes Acquisition of Mitobridge, Inc.

Show per page

Follow Us On Social Media

Stay Connected

Get only the email alerts you want.

Media Contacts

For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

Download Fact Sheet

Download Fact Sheet

Sustainability

Investors

Explore U.S. Products

Explore U.S. Products